1-2-4-trioxane and Schistosomiasis-mansoni

1-2-4-trioxane has been researched along with Schistosomiasis-mansoni* in 2 studies

Other Studies

2 other study(ies) available for 1-2-4-trioxane and Schistosomiasis-mansoni

Article	Year
In vivo activity of aryl ozonides against Schistosoma species. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2 We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound. Topics: Animals; Anthelmintics; Female; Heterocyclic Compounds; Mice; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis haematobia; Schistosomiasis mansoni; Treatment Outcome	2012
In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11 We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 microg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity. Topics: Aminoquinolines; Animals; Heterocyclic Compounds; Larva; Mice; Parasitic Sensitivity Tests; Schistosomiasis mansoni; Schistosomicides	2009

Article

Year

In vivo activity of aryl ozonides against Schistosoma species.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound.

Topics: Animals; Anthelmintics; Female; Heterocyclic Compounds; Mice; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis haematobia; Schistosomiasis mansoni; Treatment Outcome

2012

In vitro activities of trioxaquines against Schistosoma mansoni.

Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11

We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 microg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity.

Topics: Aminoquinolines; Animals; Heterocyclic Compounds; Larva; Mice; Parasitic Sensitivity Tests; Schistosomiasis mansoni; Schistosomicides

2009